Mutation News and Research

RSS

UC researchers sequence individual glioblastoma genomes and track abnormalities through the bloodstream

Medical scientists know this about glioblastoma multiforme: the malignant brain tumor is aggressive, it is elusive, and it appears in different permutations.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

AACR President-elect to host press conference on cancer risk factors and genetics

As cancer continues to affect one in two men and one in three women, researchers are increasing their knowledge on the known risk factors for cancer both environmentally and genetically.

5 Apr 2011

Known cancer-linked gene involved in subset of advanced prostate tumors

Researchers at the University of Michigan Comprehensive Cancer Center have identified a genetic anomaly that may drive the aggressive spread of a rare subset of prostate cancers.

5 Apr 2011

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

New insight into Parkinson's disease

As Parkinson's Awareness Month gets underway, a Canadian-led international study is providing important new insight into Parkinson's disease and paving the way for new avenues for clinical trials.

5 Apr 2011

Researchers identify new gene that can influence person's risk of developing epilepsy

Vanderbilt University researchers have identified a new gene that can influence a person's risk for developing epilepsy. The findings, reported in the March 29 Proceedings of the National Academy of Sciences, could improve molecular diagnostic tools and point to novel therapeutic targets for epilepsy.

5 Apr 2011

Daiichi Sankyo acquires Plexxikon

Plexxikon Inc. today announced that its acquisition by Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company, has been successfully completed. Clearance under the Hart Scott Rodino Antitrust Improvements Act has been received. Under the terms of the deal, Plexxikon shareholders will receive $805 million up-front, with near-term milestone payments associated with the approval of PLX4032 totaling an additional $130 million.

4 Apr 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

Scientists sequence tumor genomes from 50 breast cancer patients

In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells.

4 Apr 2011

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Scientists identify novel gene markers for EGFR inhibition in patients

Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Research offers first structural insights into 'client' protein shape in chaperone presence

In the constantly morphing field of protein structure, scientists at The Scripps Research Institute offer yet another surprise: a common "chaperone" protein in cells thought to help other proteins fold has been shown instead to loosen them.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

Study links chronic stress of cancer with telomere length

Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer.

4 Apr 2011

Breast cancer genome reveals potential therapeutic targets

Scientists have sequenced the entire genomes of tumors from 50 breast cancer patients and found more than 1,700 gene mutations, most of which were unique to individual patients. The researchers at Washington University in St. Louis and the Siteman Cancer Center suggest that this variability and uniqueness made it difficult to predict outcomes of the cases.

3 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Mutation News and Research

UC researchers sequence individual glioblastoma genomes and track abnormalities through the bloodstream

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

AACR President-elect to host press conference on cancer risk factors and genetics

Known cancer-linked gene involved in subset of advanced prostate tumors

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

New insight into Parkinson's disease

Researchers identify new gene that can influence person's risk of developing epilepsy

Daiichi Sankyo acquires Plexxikon

Scientists identify new treatment target for squamous cell lung cancer

Scientists sequence tumor genomes from 50 breast cancer patients

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

Scientists identify novel gene markers for EGFR inhibition in patients

Research offers first structural insights into 'client' protein shape in chaperone presence

Life Technologies launches new TaqMan Mutation Detection Assays

Study links chronic stress of cancer with telomere length

Breast cancer genome reveals potential therapeutic targets

Experts must monitor new antiviral compounds for HCV treatment

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Series of new clinical trials confirm range of viable treatment options for HCV patients

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News